Jeffrey A Sparks1,2, Yinzhu Jin3, Soo-Kyung Cho4, Seanna Vine3, Rishi Desai2,3, Tracy J Doyle2,5, Seoyoung C Kim1,2,3. 1. Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA, USA. 2. Harvard Medical School, Brigham and Women's Hospital, Boston, MA, USA. 3. Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, USA. 4. Division of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea. 5. Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Abstract
OBJECTIVE: We aimed to investigate the prevalence, incidence and cause-specific mortality of RA-associated interstitial lung disease (RA-ILD) among older US patients with RA. METHODS: We performed a nationwide cohort study using Medicare claims data (parts A, B and D for 2008-2017). RA was identified with a validated algorithm using RA diagnosis codes and DMARD prescription. RA-ILD was identified with a validated algorithm using ILD diagnosis codes by a rheumatologist/pulmonologist. RA-ILD was categorized as prevalent or incident relative to the initial RA observation (baseline/index date). We compared the total mortality of RA-ILD to RA without ILD using multivariable Cox regression, adjusting for baseline covariates. For cause-specific mortality, Fine and Gray subdistribution hazard ratios (sdHRs) were estimated to handle competing risks of alternative mortality causes. RESULTS: Among 509 787 RA patients (mean age 72.6 years, 76.2% female), 10 306 (2.0%) had prevalent RA-ILD at baseline. After baseline, 13 372 (2.6%) developed RA-ILD during 1 873 127 person-years of follow-up (median 3.0 years/person). During follow-up, 38.7% of RA-ILD patients died compared with 20.7% of RA patients without ILD. After multivariable adjustment, RA-ILD had an HR of 1.66 (95% CI 1.60, 1.72) for total mortality. Accounting for competing risk of other causes of death, RA-ILD had an sdHR of 4.39 (95% CI 4.13, 4.67) for respiratory mortality and an sdHR of 1.56 (95% CI 1.43, 1.71) for cancer mortality compared with RA without ILD. CONCLUSIONS: RA-ILD was present or developed in nearly 5% of patients in this nationwide study of older patients with RA. Compared with RA without ILD, RA-ILD was associated with excess total, respiratory and cancer mortality that was not explained by measured factors.
OBJECTIVE: We aimed to investigate the prevalence, incidence and cause-specific mortality of RA-associated interstitial lung disease (RA-ILD) among older US patients with RA. METHODS: We performed a nationwide cohort study using Medicare claims data (parts A, B and D for 2008-2017). RA was identified with a validated algorithm using RA diagnosis codes and DMARD prescription. RA-ILD was identified with a validated algorithm using ILD diagnosis codes by a rheumatologist/pulmonologist. RA-ILD was categorized as prevalent or incident relative to the initial RA observation (baseline/index date). We compared the total mortality of RA-ILD to RA without ILD using multivariable Cox regression, adjusting for baseline covariates. For cause-specific mortality, Fine and Gray subdistribution hazard ratios (sdHRs) were estimated to handle competing risks of alternative mortality causes. RESULTS: Among 509 787 RA patients (mean age 72.6 years, 76.2% female), 10 306 (2.0%) had prevalent RA-ILD at baseline. After baseline, 13 372 (2.6%) developed RA-ILD during 1 873 127 person-years of follow-up (median 3.0 years/person). During follow-up, 38.7% of RA-ILD patients died compared with 20.7% of RA patients without ILD. After multivariable adjustment, RA-ILD had an HR of 1.66 (95% CI 1.60, 1.72) for total mortality. Accounting for competing risk of other causes of death, RA-ILD had an sdHR of 4.39 (95% CI 4.13, 4.67) for respiratory mortality and an sdHR of 1.56 (95% CI 1.43, 1.71) for cancer mortality compared with RA without ILD. CONCLUSIONS: RA-ILD was present or developed in nearly 5% of patients in this nationwide study of older patients with RA. Compared with RA without ILD, RA-ILD was associated with excess total, respiratory and cancer mortality that was not explained by measured factors.
Authors: Jeffrey A Sparks; Shun-Chiao Chang; Katherine P Liao; Bing Lu; Alexander R Fine; Daniel H Solomon; Karen H Costenbader; Elizabeth W Karlson Journal: Arthritis Care Res (Hoboken) Date: 2016-06 Impact factor: 4.794
Authors: Charlotte Hyldgaard; Ole Hilberg; Alma Becic Pedersen; Sinna Pilgaard Ulrichsen; Anders Løkke; Elisabeth Bendstrup; Torkell Ellingsen Journal: Ann Rheum Dis Date: 2017-06-13 Impact factor: 19.103
Authors: Tracy J Doyle; Avignat S Patel; Hiroto Hatabu; Mizuki Nishino; Guodong Wu; Juan C Osorio; Maria F Golzarri; Andres Traslosheros; Sarah G Chu; Michelle L Frits; Christine K Iannaccone; Diane Koontz; Carl Fuhrman; Michael E Weinblatt; Souheil Y El-Chemaly; George R Washko; Gary M Hunninghake; Augustine M K Choi; Paul F Dellaripa; Chester V Oddis; Nancy A Shadick; Dana P Ascherman; Ivan O Rosas Journal: Am J Respir Crit Care Med Date: 2015-06-15 Impact factor: 21.405
Authors: Julia A Ford; Xinyi Liu; Su H Chu; Bing Lu; Michael H Cho; Edwin K Silverman; Karen H Costenbader; Carlos A Camargo; Jeffrey A Sparks Journal: Arthritis Rheumatol Date: 2020-04-03 Impact factor: 10.995
Authors: Tracy J Doyle; Paul F Dellaripa; Kerri Batra; Michelle L Frits; Christine K Iannaccone; Hiroto Hatabu; Mizuki Nishino; Michael E Weinblatt; Dana P Ascherman; George R Washko; Gary M Hunninghake; Augustine M K Choi; Nancy A Shadick; Ivan O Rosas Journal: Chest Date: 2014-07 Impact factor: 9.410
Authors: Patrick Kiely; A D Busby; E Nikiphorou; K Sullivan; D A Walsh; P Creamer; J Dixey; A Young Journal: BMJ Open Date: 2019-05-05 Impact factor: 2.692
Authors: Lauren Prisco; Matthew Moll; Jiaqi Wang; Brian D Hobbs; Weixing Huang; Lily W Martin; Vanessa L Kronzer; Sicong Huang; Edwin K Silverman; Tracy J Doyle; Michael H Cho; Jeffrey A Sparks Journal: Arthritis Rheumatol Date: 2021-09-26 Impact factor: 10.995